phone-icon(+035) 527-1710-70
email-icongoogle@gmail.com
map-iconChoose an address
Eastgate Biotech Eastgate Biotech
  • Home
  • About Us
    • Management
  • Technology
    • Research
    • Intraoral Insulin
  • Products
  • Investors
    • Press Releases
    • SEC Filings
  • Media
    • Dr. Luc Duchesne
    • Investor Intel
    • Investor Wired
    • StockHouse
    • TechSonian
    • PharmaLot
  • Contact Us
Menu
Eastgate Biotech Eastgate Biotech
  • NEWSLETTER
  • CONTACT US
  • FAQs
  • SPECIAL OFFER
  • PURCHASE THEME

Press Releases

09 Mar
Uncategorized

Eastgate Biotech Corp (OTC: ETBI) Management Interview

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
Eastgate Biotech Corp (OTC: ETBI) Management Interview   Interview with COO Bill Abajian Eastgate’s new COO took time...

Continue reading

09 Mar
Uncategorized

EastGate Biotech Announces Appointment of Bill Abajian to Lead Licensing and Marketing Phase as Chief Operating Officer

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
EastGate Biotech Announces Appointment of Bill Abajian to Lead Licensing and Marketing Phase as Chief Operating Officer WEST CALDWEL...

Continue reading

09 Mar
Uncategorized

EastGate Biotech Files Application to Initiate Phase III clinical trial for Insugin

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
Approximately 200 patients will be included in the Phase III study in order to achieve regulatory approval in Pakistan     ...

Continue reading

09 Mar
Uncategorized

Bill Abajian of EastGate Biotech Corp. to speak at the 2019 M&A Forum for Pharma, Biotech and Med Device to be held between August 12 – 14, 2019 in Philadelphia

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
Forum to focus on Innovative Partnership Opportunities for Product, Portfolio and Market Development     WEST CALDWELL, NJ...

Continue reading

09 Mar
Uncategorized

EastGate Biotech Announces Preparation to Initiate Phase III Clinical Trials on Insugin, its Liquid Insulin Mouth Rinse for Type 2 diabetes patients

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
Multi-Center Phase III trial planned for 2019 WEST CALDWELL, NJ and TORONTO, ON /NEWMEDIAWIRE/ May 15, 2019/ Eastgate Biotech Co...

Continue reading

09 Mar
Uncategorized

EastGate Biotech Announces Positive Phase II Clinical Results of its Innovative Liquid Insulin Mouth Rinse Solution for Type 2 Diabetes

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
Following a 3-month treatment, significant Hb1c Reduction was observed with administration of a single dose of Insugin two times a ...

Continue reading

09 Mar
Uncategorized

Eastgate BioTech Corp (OTCBB: ETBI) Interview with CEO Anna Gluskin

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
https://wallstreetanalyzer.com/2019/04/09/eastgate-biotech-corp-otcbb-etbi-interview-with-ceo-anna-gluskin/

Continue reading

09 Mar
Uncategorized

Eastgate Biotech Signs Strategic Alliance Agreement with MJ Biopharm for Insulin API Supply

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
Alliance with MJ Biopharm of Mumbai, India positions the company to further its plans for SEA countries for its liquid insulin mout...

Continue reading

09 Mar
Uncategorized

EastGate Biotech Attends Arab Health Conference Seeking Additional Joint Venture Partnerships

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
e both our JV partner and Bill represent Eastgate at the conference,” said Anna Gluskin CEO of Eastgate Biotech.  “Not only can they sp...

Continue reading

09 Mar
Uncategorized

EastGate Biotech Appoints Additional Consultants in Preparation of Progressing Company Developments in 2019

  • March 9, 2022
  • By author-avatar admin
  • 0 comments
WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / December 17, 2018 / Eastgate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical comp...

Continue reading

  • ‹
  • 1
  • 2
  • 3
  • 4
  • ›
  • »

EastGate Biotech produces and distributes innovative and healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body.

2203-65 Harbour Square Toronto, Ontario M5J 2L4 Canada
Phone: +1 647 692 0652
WhatsApp: +1 647 692 0652
Our Office
  • New York
  • London SF
  • Cockfosters BP
  • Los Angeles
  • Chicago
  • Las Vegas
Innovative Alternatives to Conventional Pharmaceuticals.
  • Home
  • About Us
    • Management
  • Technology
    • Research
    • Intraoral Insulin
  • Products
  • Investors
    • Press Releases
    • SEC Filings
  • Media
    • Dr. Luc Duchesne
    • Investor Intel
    • Investor Wired
    • StockHouse
    • TechSonian
    • PharmaLot
  • Contact Us
  • Compare